Rosiglitazone for HIV-1 lipoatrophy

被引：2

作者：

Cavalcanti, RB ^{[1
]}

Raboud, J

Kain, KC

Walmsley, S

机构：

[1] Univ Toronto, Dept Med, Toronto, ON M4V 1C6, Canada

[2] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M4V 1C6, Canada

来源：

LANCET | 2004年 / 363卷 / 9423期

关键词：

D O I：

10.1016/S0140-6736(04)16318-6

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：1828 / 1829

页数：2

共 4 条

[1]

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial [J].

Carr, A ;

Workman, C ;

Carey, D ;

Rogers, G ;

Martin, A ;

Baker, D ;

Wand, H ;

Law, M ;

Samaras, K ;

Emery, S ;

Cooper, DA .

LANCET, 2004, 363 (9407) :429-438

[2]

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy [J].

Mallon, PWG ;

Miller, J ;

Cooper, DA ;

Carr, A .

AIDS, 2003, 17 (07) :971-979

[3]

Managing HIV lipoatrophy [J].

Moyle, G ;

Sutinen, J .

LANCET, 2004, 363 (9407) :412-414

[4]

A 48-week, randomized, open-label comparison of three Abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy [J].

Moyle, GJ ;

Baldwin, C ;

Langroudi, B ;

Mandalia, S ;

Gazzard, BG .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (01) :22-28

← 1 →